Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a law to strengthen the legal framework for drug quality testing and market surveillance, along with regulation of medical devices and cosmetics.
One of the major reasons behind the drafting of the law is the repeated complaints and concerns flagged by health regulators across the globe, including the WHO, over serious quality lapses by Indian drug manufacturers.
The draft of the ‘Drugs, Medical Devices and Cosmetics Act 2025’, which the government aims to introduce in the upcoming Winter session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi at a high-level meeting of the Union health ministry held on Tuesday, the sources said.
The meeting was chaired by Union Health Minister J P Nadda.
During the meeting, senior officials from the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control
